FDA Signals Support for Leqembi and Nirsevimab in Upcoming AdComms

Eisai’s Leqembi and AstraZeneca’s nirsevimab are both poised for a greenlight from the FDA if agency briefing documents prepared for two advisory committee meetings this week are any indication.
Source: Drug Industry Daily